Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMüge Çevik, Borisov Se, Caryn M. Upton et al.|The Lancet Infectious Diseases|2024Cited by 60